Hjem › Brystkreft › Oregon
Kliniske studier for Brystkreft i Oregon
41 studier for Brystkreft søker deltakere på steder i Oregon.
Byer i Oregon
- Portland33 studier
- Beaverton8 studier
- Eugene7 studier
- Salem5 studier
- Bend4 studier
- Corvallis3 studier
- Gresham3 studier
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon PC, Eugene
- Northwest Cancer Specialists, Portland
- og 1 flere
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 7 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Compass Oncology - Rose Quarter Cancer Center, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07701941A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT05877599Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8010), Tigard
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Providence Portland Medical Center ( Site 0044), Portland
- Providence St. Vincent Medical Center ( Site 0081), Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312176ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oregon Health and Science University, Portland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Local Institution - 0052, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07085767A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Good Samaritan Regional Medical Center, Corvallis
- Oncology Associates of Oregon, Eugene
- Oregon Health and Science University, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 22. sep. 2026 · NCT07287098ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- St Charles Bend Cancer Center, Bend
- Providence Portland Medical Center, Portland
- St. Charles Cancer Center - Redmond, Redmond
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07173751A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Providence Cancer Institute Franz Clinic, Portland
- Providence Cancer Institute Franz Clinic, Portland
- Oregon Oncology Specialists, Salem
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Providence Cancer Institute, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06253871A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Oncology Associates of Oregon, P.C, Eugene
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07100106Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Oregon Health & Science University, Knight Cancer Institute, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06982521A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Cancer Clinic - Westside;Investigation Drug Services Pharmacy, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06790693Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 10 flere
RekruttererFase 3
Alder 18 til 60 · Kvinner · Oppdatert 2. sep. 2026 · NCT05879926A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Willamette Valley Cancer Institute, Eugene
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 10. aug. 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Hematology Oncology Associates, Medford
- Compass Oncology - Northwest Cancer Specialists, Tigard
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT05232916Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Saint Charles Health System, Bend
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- og 6 flere
RekruttererFase 3
Alder 18 til 50 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06748222Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
- Samaritan Pastega Regional Cancer Center, Corvallis
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 17. jul. 2026 · NCT07055854Identifying and Caring for Individuals With Inherited Cancer Syndrome
- Providence Portland Medical Center, Portland
- OHSU Knight Cancer Institute, Portland
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 14. jul. 2026 · NCT04494945First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jul. 2026 · NCT05768139Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
- Oncology Associates of Oregon, Springfield
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. jul. 2026 · NCT07558733177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
- OHSU Knight Cancer Institute, Portland
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 5. jun. 2026 · NCT04529044I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Oregon Health & Science Institute (OHSU), Portland
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT01042379De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Clackamas Radiation Oncology Center, Clackamas
- Legacy Mount Hood Medical Center, Gresham
- Providence Newberg Medical Center, Newberg
- og 5 flere
RekruttererFase 3
Alder 50 til 70 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT04852887Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 og eldre · Alle kjønn · Oppdatert 20. jan. 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. okt. 2025 · NCT03418961MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Willamette Valley Cancer Institute and Research Center, Eugene
- Legacy Good Samaritan Medical Center, Portland
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2025 · NCT03053193EMBRACE: Exercising Together
- OHSU Knight Cancer Institute, Portland
RekruttererFase 2Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 29. mai 2025 · NCT06049355Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.